SPECIAL NOTICE
A -- DNA Sequencing
- Notice Date
- 6/18/2010
- Notice Type
- Special Notice
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- HHS-FDA-RFI-1071987
- Archive Date
- 7/7/2010
- Point of Contact
- Tara R. Hobson, Phone: 3018279691, Doreen Williams, Phone: 3018273366
- E-Mail Address
-
Tara.Hobson@fda.hhs.gov, doreen.williams@fda.hhs.gov
(Tara.Hobson@fda.hhs.gov, doreen.williams@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- Description: Roche 454 pyrosequencing, and Illumina ultra deep sequencing service for viral vaccine analysis within the laboratory of method development/Division of Viral Products/Office of Vaccines This is a RFI to determine the availability and capability of small businesses (i.e., certified 8(a), Small Disadvantaged, and HUBZone firms; veteran and service-disabled veteran-owned small businesses, and woman-owned small businesses) for Roche 454 pyrosequencing, and Illumina ultra deep sequencing service for viral vaccine analysis within the laboratory of method development/Division of Viral Products/Office of Vaccines. This information is being sought for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Food and Drug Administration (FDA). No official solicitation exists; therefore, please do not request a copy of a solicitation. If in the future an official solicitation is released, there is no guarantee that sources responding to this will be included on the source list. No telephone inquiries will be accepted. 001 DNA Sequencing Using Roche (454)-1 each 002 Library Construction of DNA Samples-2 each 003 DNA Sequencing Using Illumina-5 each Draft Scope of Work: 1. The sequencing data may be used for discovery and quantification of mutants in batches of viral vaccines. 2. The requirement of this service is the maximum redundancy in sequencing, meaning that results for each sample must include tens of thousands of individual sequence determinations (reads) 3. Sequencing may be run on Roche's 454 instrument (also called pyrosequencing technology) AND Illumina's Genome Analyzer (GA) IIx. 4. Both instruments above may be used in the aforementioned project for its different aspects, as this requirement is for the Laboratory of Method Development and as such requires evaluation of various methodologies/technologies. Draft Technical Requirements: 1. Contractor may analyze samples of Amplified cDNA prepared from vaccine samples and vaccine derived viruses utilizing Roche's 454 instrument (also called pyrosequencing technology) 300-400 bp in length and Illumina's Genome Analyzer (GA) IIx, which shall be 30-100 bp in length. 2. Contractor may use both instruments listed above concurrently in this project for its different aspects, as this requirement is for the Laboratory of Method Development and as such requires evaluation of various methodologies/technologies. 3. Contractor may use process user furnished cDNA samples using user furnished protocols for both deep sequencing/454 methodologies and provide sequencing data. 4. Contractor may use overnight turn-around for the entire service, e.g. pick up of samples-sequencing providing results, but not to exceed 48-72 hour turn around. 5. Contractor may provide sequencing data results utilizing both methodologies/technologies via secure web, CD and/or both. Deliver sequencing data results via secured web/internet connection (which is preferred due to immediate access to results.) We may anticipate a firm fixed price purchase order. Viable parties shall provide the following: Part A. Capabilities and Technical Experience - Provide a capability statement describing how your company would provide Roche 454 pyrosequencing, and Illumina ultra deep sequencing service for viral vaccine analysis within the laboratory of method development/Division of Viral Products/Office of Vaccines. Part B. Size of Business- Please provide your business size and submit copies of any documentation such as letters or certificates to indicate the firm's status. Part C. Organizational Conflict of Interest (OCI) - If any, provide disclosure of business activities of your company, your affiliates, your team members and affiliates of your team members which create either a conflict of interest or the appearance of a conflict of interest in Roche 454 pyrosequencing, and Illumina ultra deep sequencing service for viral vaccine analysis within the laboratory of method development/Division of Viral Products/Office of Vaccines. Part D. Cost Estimate - Provide a cost estimate in accordance with FAR Part 10, Market Research for Roche 454 pyrosequencing, and Illumina ultra deep sequencing service for viral vaccine analysis within the laboratory of method development/Division of Viral Products/Office of Vaccines. Part E. Small Business - Describe your ability to meet the requirements in accordance with 52.219.14 - Limitation on Subcontracting. Responses shall be:  identified with the RFI number ;  no more than ten (10) pages in length;  not submit marketing materials;  submitted to the email as indicated above. FDA makes no implied or in fact contract by issuing this RFI. Acknowledgement of receipt of responses will not be made, nor will respondents be notified of the FDA's view of the information received.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/HHS-FDA-RFI-1071987/listing.html)
- Record
- SN02182165-W 20100620/100618234856-970498074613992eede8e39cdb3d143b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |